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BRCA1 accumulation at DNA damage sites is an important step for its function in the 26 
DNA damage response and in DNA repair. BRCA1-BRCT domains bind to proteins 27 
containing the phosphorylated serine-proline-x-phenylalanine (pSPxF) motif 28 
including Abraxas, Bach1/FancJ and CtIP. In this study, we demonstrate that ionizing 29 
radiation (IR)-induces ATM-dependent phosphorylation of serine 404 (S404) next to 30 
the pSPxF motif. Crystal structures of BRCT/Abraxas show that phosphorylation of 31 
S404 is important for extensive interactions through the N-terminal sequence outside 32 
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the pSPxF motif and leads to formation of a stable dimer. Mutation of S404 leads to 33 
deficiency in BRCA1 accumulation at DNA damage sites and cellular sensitivity to 34 
IR. In addition, two germline mutations of BRCA1 are found to disrupt the dimer 35 
interface and dimer formation. Thus, we demonstrate a mechanism involving IR-36 
induced phosphorylation and dimerization of the BRCT/Abraxas complex for 37 
regulating Abraxas-mediated recruitment of BRCA1 in response to IR. 38 
 39 
Introduction 40 
Patients with hereditary breast and ovarian cancer (HBOC) have high germline gene-41 
mutation rates on chromosome 17q21 tumor suppressor gene BRCA1 (breast cancer 42 
susceptibility genes 1) (Futreal et al., 1994; Hall et al., 1990; Miki et al., 1994). 43 
BRCA1 stabilizes genomic integrity by interacting with various DNA damage 44 
response (DDR) sensors, mediators and effector proteins, thereby coordinating 45 
recognition of the DNA damage sites, cell cycle checkpoint, DNA repair, 46 
transcription and apoptosis/senescence. BRCA1, a large protein of 1863 amino acids, 47 
contains an N-terminal RING domain and two C-terminal tandem BRCT domains. 48 
BRCT domains can recognize phosphorylated proteins with a pSPxF motif (Manke et 49 
al., 2003; Rodriguez et al., 2003; Yu et al., 2003) including Abraxas (Kim et al., 50 
2007a; Liu et al., 2007; Wang et al., 2007), Bach1/FancJ (Cantor et al., 2001; Yu et 51 
al., 2003) and CtIP (Wong et al., 1998; Yu et al., 1998). The phosphopeptide-binding 52 
ability of BRCA1 BRCT is essential for BRCA1’s tumor suppression function 53 
(Shakya et al., 2011), where many breast and ovarian cancer related mutations occur 54 
(Clapperton et al., 2004; Couch and Weber, 1996; Friedman et al., 1994; Shattuck-55 
Eidens et al., 1995; Shiozaki et al., 2004; Williams et al., 2004). 56 
The two BRCA1-BRCT domains (BRCT1 and BRCT2) each contain about 100 57 
residues and associate in a head-to-tail manner (Williams et al., 2001). Structural 58 
analysis of BRCA1-BRCT domains with pSPxF-containing phosphopeptides of 59 
Bach1 (Clapperton et al., 2004, Shiozaki et al., 2004;), CtIP (Varma et al., 2005), 60 
syntheic optimized phosphopetide (Williams et al., 2004) or other binding proteins 61 
(Campbell et al., 2010; Liu and Ladias, 2013; Shen and Tong, 2008) have revealed 62 
that phosphorylated serine and phenylalanine in the pSPxF motif bind in a cleft 63 
formed at the junction of two BRCT domains in a “two-anchor” mode and the 64 
structural integrity of both binding sites is essential for peptide recognition (Glover et 65 
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al., 2004; Leung and Glover, 2011; Wu et al., 2015). However, little information 66 
exists regarding the importance of the sequence sourrounding the pSPxF motif. Nor is 67 
it known how the specificity is determined for BRCT binding to different pSPxF 68 
motif-containing proteins. 69 
Abraxas mediates the interaction of BRCA1 to other components of the 70 
BRCA1-A complex, which include BRCC36, NBA1/MERIT40, BRE and Rap80.  71 
Abraxas, a 409-residue polypeptide, contains a non-catalytic MPN (Mpr1, Pad1 N-72 
terminal) domain at its N-terminus, followed by a coiled-coil (CC) region, an 73 
unstructured region and a BRCA1-binding pSPTF motif at the C-terminus. While the 74 
N-terminal region including the MPN domain binds to Rap80, BRE and 75 
NBA1/MERIT40, the coil-coil domain is required for interaction with BRCC36 (Hu 76 
et al., 2011; Kim et al., 2007a; Wang and Elledge, 2007; Wang et al., 2009). Although 77 
the structures for BRCA1 BRCT in complex with other phosphopeptides have been 78 
solved previously (Campbell et al., 2010; Clapperton et al., 2004; Liu and Ladias, 79 
2013; Shen and Tong, 2008; Shiozaki et al., 2004; Varma et al., 2005; Williams et al., 80 
2004), the structure for BRCT/Abraxas has remained unknown.             81 
Abraxas and the BRCA1-A complex recruits BRCA1 to DNA-damage 82 
double-stand-break sites (DSBs) in an ATM-dependent ubiquitin-mediated signaling 83 
pathway involving E2 conjugase Ubc13, E3 ligases RNF8/RNF168 and Rap80 84 
binding to ubiquitin lys63-linked polyubiquitin conjugates (Doil et al., 2009; Harper 85 
and Elledge, 2007; Hu et al., 2012; Huen and Chen, 2007; Kim et al., 2007b; Kolas et 86 
al., 2007; Lee and Paull, 2004; Mailand et al., 2007; Sato et al., 2009; Uziel et al., 87 
2003; Wang, 2012; Wang and Elledge, 2007; Wu et al., 2009). Abraxas-deficient 88 
mice exhibit decreased survival and increased tumor incidence (Castillo et al., 2014). 89 
The interaction of Abraxas with BRCA1 has been shown critical for the function of 90 
Abraxas in DNA repair of DSBs and maintenance of genomic stability. Mutation of 91 
the serine residue in the pSPxF motif leads to defective DNA repair and chromosome 92 
aberration. The importance of the Abraxas-BRCA1 interaction in tumor suppression 93 
is also suggested by identification of an Abraxas mutation in tumor in the 94 
phenylalanine residue of the pSPxF motif (F409C) (Castillo et al., 2014). Thus, 95 
structural and functional analysis of Abraxas and BRCA1 interaction is necessary to 96 
facilitate the understanding of Abraxas-mediated BRCA1 signaling in tumor 97 
suppression.  98 
In this study, we have solved the crystal structures of BRCT with Abraxas 99 
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phosphorylated peptides and revealed an IR-induced, ATM-dependent Abraxas 100 
phosphorylation mechanism, which promotes dimerization of BRCT/Abraxas 101 
complex at the DNA damage sites. The IR-induced phosphorylation of Abraxas and 102 
the subsequent stabilization of BRCA1-BRCT dimerization are likely to comprise an 103 
important mechanism for accumulation of BRCA1 to DNA-damaged chromatin and 104 
BRCA1 mediated tumor suppression. 105 
 106 
Results 107 
Abraxas is double phosphorylated at S404 and S406 residues in response to IR  108 
Analysis of the C-terminal sequence of Abraxas reveals an additional serine (S404) 109 
located close to the pSPxF motif (Figure 1A). Double-phosphorylated Abraxas 110 
peptide containing phosphorylated S406 and S404 (GFGEYpS404RpS406PTF) has 111 
been identified to bind to BRCA1-BRCT domains in response to IR (Wang et al., 112 
2007). We decided to investigate whether the S404 residue is important and whether 113 
it is phosphorylated upon IR. Previously we have generated S406 phospho-specific 114 
antibody and showed that phosphorylation of S406 (pS406) occurs independently of 115 
IR (Wang et al., 2007). In view of the fact that S406 is nearby and is phosphorylated 116 
in the presence and absence of IR, we generated antibodies specifically recognizing 117 
double-phosphorylated S404 and S406 (pS404pS406). The pS404pS406 specific 118 
antibody recognized Abraxas in parental but not Abraxas knockout 293T cells and the 119 
intensity of the Abraxas band increased significantly when cells were treated with IR, 120 
indicative of IR-induced phosphorylation (Figure 1B). Mutation of either S404 121 
(S404A), S406 (S406A) or double mutation (S404A, S406A) abolished the 122 
recognition of Abraxas by the pS404pS406 antibody (Figure 1C). Upon IR treatment, 123 
double phosphorylation of Abraxas S404 and S406 residues increased immediately 124 
(within 10 minutes), peaked at 1 h and gradually decreased to nearly basal levels at 125 
later time points (Figure 1D). Furthermore, double phosphorylation occurs in a dose-126 
dependent manner in response to IR (Figure 1E). Since phosphorylation of S406 is 127 
not changed upon IR treatment, phosphorylation of S404 is likely to be IR-induced. 128 
As ATM plays a central role in the IR-induced signaling pathway that recruits 129 
Abraxas and the BRCA1-A complex (Harper and Elledge, 2007), we investigated 130 
whether ATM regulates the phosphorylation. Indeed, the IR-induced S404 131 
phosphorylation is ATM dependent, treatment of an ATM inhibitor KU55933 132 
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completely abolished the IR-induced phosphorylation (Figure 1F). Other DNA 133 
damage response kinases including ATR, DNA-PK, Chk1 or Chk2, however, did not 134 
appear to have a major effect on the-IR induced phosphorylation recognized by the 135 
pS404pS406 antibody (Figure 1G and S1). 136 
 137 
Crystal structures of BRCA1 BRCT domains in complex with single and double 138 
phosphorylated Abraxas peptides 139 
Since S404 is separated by just one residue from S406, which is part of the pSPxF 140 
motif, we hypothesized that an additional mechanism exploiting phosphorylation of 141 
S404 might regulate Abraxas interaction with BRCA1. In order to test this we used 142 
structural information to allow comparison of the interactions between BRCT and 143 
Abraxas in single and double phosphorylated states. We solved crystal structures of 144 
BRCA1-BRCT in complex with both single (1p) and double-phosphorylated (2p) 145 
synthesized Abraxas peptides (Ab). The BRCT-Ab1p (GFGEYSRpSPTF) complex 146 
crystal was solved at 3.5 Å resolution with no clear main-chain electron density for 147 
the N-terminal GFGE region of the peptide, indicating that this region is flexible. 148 
BRCT-Ab1p_short without the GFGE residues (YSRpSPTF) complex was then 149 
crystalized and solved at 2.5 Å resolution. The structure of BRCT domains in 150 
complex with the double phosphorylated Abraxas peptide (Ab2p: 151 
GFGEYpSRpSPTF) was solved at 3.5 Å resolution. However, the BRCT-Ab2p_short  152 
(YpSRpSPTF) crystal did not diffract to a high resolution. We therefore used BRCT-153 
Ab1p_short and BRCT-Ab2p structures (Figure 2A, S2A) for analysis. Statistics of 154 
these two structures are shown in Supplemental Table S1. 155 
            As in structures solved previously (Campbell et al., 2010; Clapperton et al., 156 
2004; Liu and Ladias, 2013; Shen and Tong, 2008; Shiozaki et al., 2004; Varma et al., 157 
2005; Williams et al., 2001, 2004), two BRCT domains of BRCA1 (BRCT1 and 158 
BRCT2) associate in a head-to-tail manner in both structures. In each domain, a four-159 
stranded parallel β-sheet is surrounded by three α-helices with α1 and α3 on one side 160 
of the β-sheet and α2 on the other side. Helices α2 (from BRCT1), α′1 and α′3 (from 161 
BRCT2) form the hydrophobic interface, and the two domains are further linked by 162 
extra helix αL (Figure 2A, E). The pSPTF motif from Abraxas binds to the BRCT 163 
domains in a similar “two-anchor” mode using pS406 and F409. Residues P407 and 164 
T408 do not make major interactions with the BRCT domains. The phosphate group 165 
of Abraxas S406 interacts with the side chains of BRCT K1702 and S1655, as well as 166 
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the main chain of G1656 (Figure 2B). The side chain of F409 in Abraxas inserts into 167 
the BRCT hydrophobic pocket created by L1701, F1704, N1774, M1775 and L1839 168 
(Figure 2C). As F409 is the terminal residue for Abraxas, an extra salt bridge is 169 
present between the main chain carboxyl group of F409 with the BRCT domain 170 
residue R1699 (Figure 2D). This extra interaction was seen in previous structures 171 
using tetrapeptides pSPTF (Campbell et al., 2010).  172 
           A notable difference between BRCT-Ab2p and BRCT-Ab1p_short structure is 173 
the conformation of the Y403S404R405 region (Figure 2E, F and G). Extra electron 174 
density corresponding to the phosphate group of pS404 and the side chain of Y403 is 175 
observed only in BRCT-Ab2p. Unlike pS406, the pS404 phosphate group is oriented 176 
away from the BRCT domains into the solvent region, thus avoiding contact with 177 
G1656, L1657 and T1658 (Figure 2G). In BRCT-Ab2p, the Y403 side chain is 178 
positioned to interact through a hydrophobic interaction with BRCT P1659 at the N-179 
terminus of BRCT1 α1. The extra interaction could explain the increased proximity of 180 
α1 towards the N-terminus of the Abraxas phosphopeptide in BRCT-Ab2p compared 181 
to BRCT-Ab1p_short (Figure S3A). Superimposition of all available BRCA1 BRCT 182 
related crystal structures also showed that α1 movement towards the phosphopeptide 183 
is most prominent in BRCT-Ab2p (Figure S2B). It indicates that one of the roles of 184 
pS404 is to fix the side chain of Y403, which is conserved in higher organisms 185 
(Figure 2I), such that a trans peptide bond can form and collision is avoided. 186 
Superimposition of the BRCT/Abraxas structures with the BRCT/Bach1 (PDB 187 
code:1T29) (Shiozaki et al., 2004) and BRCT/CtIP structures (PDB code: 1Y98) 188 
(Varma et al., 2005) shows similar pSPxF-motif binding. However, compared to 189 
Bach1 and CtIP, the N-terminal sequence of Abraxas in both BRCT-Ab1p and 190 
BRCT-Ab2p structures exits on the opposite side, close to the α1 of BRCT1 domain 191 
(Figure 2H).  Interestingly, a similar side chain arrangement was also seen in BRCA1 192 
BRCT bound with “optimized peptide” (GAAYDIpSQVFPFAKKK) (PDB code: 193 
1T2V) (Williams et al., 2004) (Figure S3C), in which the tyrosine residue (Y) at -3 194 
position (phosphorylated serine in pSxxF motif as 0 position) and negatively charged 195 
residues glutamic acid (E) or aspartic acid (D) at -2 position were shown more 196 
favored for interaction with BRCA1 BRCT domains (Manke et al., 2003; Rodriguez 197 
et al., 2003).  198 
 199 
Dimerization of BRCT-Abraxas complex in crystal structures 200 
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There are eight copies of BRCT-Ab2p in the asymmetric unit (ASU), and each 201 
BRCT-Ab2p appears to dimerize through the same interface either within the ASU or 202 
between asymmetric units (Figure S2B). The dimerization of the 1:1 BRCT-Ab2p 203 
complex results in a 2:2 BRCT/Abraxas complex dimer. Dimerization involves α1 204 
and β2 of the BRCT1 domain and the Ab2p (Figure 3A, B, C, D) burying about 1880 205 
Å2 area. In the dimer interface, two of the α1 helices from each BRCT-Ab2p complex 206 
form isologous interactions burying a hydrophobic patch formed by F1662, M1663 207 
and Y1666 with aromatic side chains stacking on each other (Figure 3B). Interestingly, 208 
BRCA1 germline mutations of F1662 (F1662S) and M1663 (M1663K) have been 209 
identified in germline cancer patients as recorded in the Breast Cancer Information 210 
Core database (Szabo et al., 2000). Extensive hydrogen bonds also form between the 211 
two equivalent antiparallel β2 strands (Residues T1675-L1679) (Figure 3D). The two-212 
fold symmetry axis within the BRCA1/Abraxas dimer lies perpendicular to the two β-213 
strands. The cross interaction between the two BRCT/Abraxas complexes is also 214 
mediated by the ionic interaction between Abraxas and BRCT α1 of the opposite 215 
BRCT/Abraxas complex. The negative surface patch, generated by the phosphate 216 
group of pS404 and side chain of E402 at the N-terminus of Ab2p peptide, leads to 217 
cross interaction with BRCT K1671 (Figure 3C). The phosphate group of pS406 also 218 
contributes to the dimer formation by interacting with the R1670 residue of the 219 
opposite BRCT (Figure 3C). Although a similar dimer interface was observed for 220 
BRCT-Ab1p_short structure, the cross interaction between the negative surface patch 221 
(formed by the phosphate group of pS404 and the side chain of E402) and BRCT 222 
K1671 is completely lacking. 223 
Compared to the monomeric BRCT/Abraxas complex, where pS406 is half 224 
surrounded by BRCT1 and half exposed to the solvent, the dimerization of 225 
BRCT/Abraxas allows the second BRCT1 to reduce further the accessibility of pS406 226 
to solvent (Figure 3E).  227 
 228 
BRCT/double-phosphorylated Abraxas complex forms a dimer in vitro 229 
To examine whether the BRCT/Abraxas complex exists as a dimer in vitro, we first 230 
tested whether dimers form in solution using size exclusion chromatography at 231 
protein concentration (1 mg/ml), much lower than the concentration used for 232 
crystallization (30 mg/ml). The elution profiles of BRCT-Ab1p and BRCT-Ab2p 233 
were different. The BRCT-Ab2p elution peak appeared to the left of the BRCT-Ab1p 234 
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peak (Figure 3E), suggesting a larger hydrodynamic radius and a possible higher 235 
order BRCT-Ab2p complex. The controls show that BRCT does not interact with 236 
unphosphorylated Abraxas peptide or phosphopeptide containing only phosphorylated 237 
S404 (Figure S3A). Under the same condition, the BRCT-Bach1 and BRCT-CtIP 238 
form complexes similar to that of BRCT-Ab1p (Figure 3F). Standard protein markers 239 
were also run and the positions of their elution peaks are indicated in Figure 3F. The 240 
size of BRCT-Ab2p is roughly double that of BRCT-Ab1p according to the protein 241 
markers. 242 
            We tested whether a higher concentration of BRCT-Ab1p leads to dimer 243 
formation as we observed in crystals. Indeed, the BRCT-Ab1p peak shifts left to the 244 
BRCT-Ab2p peak position once the concentration is increased (Figure S3B), 245 
indicating the tendency of BRCT-Ab1p to form higher order complexes at high 246 
protein concentrations as observed in the crystal structure. It is likely that at high 247 
concentrations, the BRCT-Ab1p complex is packed in a conformation that is not 248 
stable at low protein concentrations without a contribution from phosphorylated S404. 249 
Therefore stable dimerization of two BRCT/Abraxas complexes is unique for  BRCT-250 
Ab2p. 251 
           To confirm dimer formation, we also measured the exact molecular weight of 252 
peak fractions eluted from gel filtration using nano-electrospray mass spectrometry 253 
analysis under native conditions (Figure 3G, H). BRCT-Ab1p is shown to exist 254 
predominantly as a 1:1 complex with a small portion forming a 2:2 dimer. In contrast, 255 
the majority of BRCT-Ab2p is detected as 2:2 complexes, indicating a much more 256 
stable dimer. BRCT/Bach1 and BRCT/CtIP are detected only as 1:1 complexes. 257 
Consistent with the finding that higher protein concentration facilitates dimer 258 
formation (Figure 4B), the proportion of BRCT-Ab1p forming dimer increases 259 
significantly when the protein concentration is increased from 15 μM to 75 μM 260 
(Figure S3F). Small angle X-ray scattering (SAXS) experiments of the BRCT-Ab1p 261 
and BRCT-Ab2p also show similar results (Figure S4). Thus, our results indicate that 262 
only double-phosphorylated Abraxas C-terminal peptide induces stable dimerization 263 
of BRCT/Abraxas complexes in vitro.  264 
 265 
Mutagenesis studies of BRCT-Ab2p dimer interface reveal the importance of 266 
S404 phosphorylation and residues of BRCA1 germline mutations for stable 267 
BRCT/Abraxas dimer formation 268 
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In order to test the dimer interface, we have generated various mutants for both BRCT 269 
domains and Abraxas (summarized in Figure 4C with peptide sequence indicated) 270 
based on the crystal structure. As shown in a simplified graph of the dimer interface 271 
(Figure 4A), three regions of interactions appear to contribute to formation of the 272 
dimer interface: 1) the N-terminal hydrophobic region of BRCT D1-D1; 2) extensive 273 
hydrogen bonds formed by E2-E2; 3) the N-terminal region of Ab2p including the 274 
phosphorylated S404 interaction with BRCT D1. The interacting residues in α1-α1 275 
and Ab2p-α1 are shown in Figure 4B.  276 
           By size exclusion chromatography, we first tested the importance of S404 277 
phosphorylation. Mutations of Abraxas S404 to proline and aspartic acid were tested. 278 
While BRCT-Ab1p (S404P) leads to 1:1 complex formation, BRCT-Ab1p (S404D) 279 
can maintain the 2:2 complex dimer as BRCT-Ab2p (Figure 4D).  This confirms that 280 
S404 phosphorylation is essential for dimerization. A previous report using optimized 281 
peptide containing aspartic acid in the equivalent position to Abraxas S404 was 282 
reported not forming dimer in solution (Williams et al., 2004). We reasoned that the 283 
difference between the optimized peptide and Ab2p is in the N-terminal region 284 
(G399F400G401E402) of Ab2p. We demonstrated that BRCT-Ab2p_short without GFGE 285 
still forms a dimer indicating that GEGE is not absolutely required for dimerization 286 
when Y403 and pS404 are present. However, when we analyzed BRCT-Ab2p in 287 
solution, we found that while F400D did not affect dimer formation, E402R as well as 288 
BRCT K1671E, R1670E partially destabilizes dimer formation and double mutation 289 
of BRCT(K1671E)-Ab2p(E402R) further destabilized the complex, eluting at a 290 
position close to that of 1:1 stoichiometry (Figure 4E). These results indicate that 291 
although GFGE is not absolutely required for the dimer formation, it contributes to 292 
the dimer stabilization when it is present. 293 
            We also tested the importance of the BRCT P1659 interaction with Abraxas 294 
Y403 to the stability of the BRCT-Ab2p dimer. In the presence of the N-terminal 295 
region (GFGE) of Ab2p, mutation of Abraxas Y403A did not destabilize the dimer 296 
complex formation in either BRCT-Ab2p(Y403A) or BRCT(P1659G)-Ab2p(Y403A). 297 
But when the N-terminal region of Abraxas was absent, the dimer complex of BRCT-298 
Ab2p(Y403A_short) became unstable. This destabilization was further enhanced in 299 
BRCT(P1659G)-Abraxas(Y403A)_short complex, which was eluted near the 1:1 300 
complex (Figure 4F). Together, these results are consistent with the crystal structure 301 
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analysis showing that double-phosphorylated Ab2p promotes dimer formation in two 302 
different ways: 1) phosphorylated S404 fixes the side chain of Y403, which generates 303 
additional interaction with BRCT K1671; 2) the phosphorylated group of pS404 and 304 
E402 form a negative surface region that leads to cross interaction with BRCT K1671.  305 
           We then evaluated the contribution of the hydrophobic interactions between 306 
the D-helices (D1-D1) and the extensive hydrogen bonds between the two antiparallel 307 
E strands (E2-E2) in the two protomers that comprise the dimer (Figure 4G). Our 308 
results indicate that the D1-D1 interaction contributes more significantly towards the 309 
stabilization of the dimer interface than the E2-E2 interaction. The BRCT mutant 310 
N1678A, which disrupted the E2-E2 interaction (Figure 3D), reduced hydrogen bonds 311 
between the side chain of N1678 and the nearby residue T1675, but did not 312 
destabilize BRCT-Ab2p dimer formation. In contrast, F1662S and M1663K, two 313 
BRCA1 germline mutations identified in cancer patients (Szabo et al., 2000), led to 314 
complete disruption of the dimer formation as the elution peaks of these two mutants 315 
in complex with Ab2p moved to the 1:1 complex position. BRCT Y1666A mutant did 316 
not result in complete disruption of the dimer and the peak in the elution profile is 317 
located between that for the 2:2 and 1:1 complexes. These results support our 318 
observation from the crystal structure that F1662S and M1663K have a much more 319 
significant effect on disruption of the dimer interface because these two residues are 320 
located at the point of the isologous dimer interface while Y1666A is further away.  321 
 322 
Abraxas S404 is important for cellular resistance to IR and accumulation of 323 
BRCA1 at the DNA damage site 324 
Since IR-induced phosphorylation of S404 appears to promote stable BRCT/Abraxas 325 
dimer formation, the S404 residue is likely to be critical for the function of Abraxas in 326 
response to IR. We first tested whether S404 is important for the cellular response to 327 
IR. In an IR sensitivity assay, both S404A and S406A mutants of Abraxas were 328 
unable to fully rescue the increased sensitivity of Abraxas knockdown cells as the 329 
wild-type Abraxas did (Figure 5A, 5B and S5), suggesting that phosphorylation of 330 
S404 plays a role in the cellular resistance to IR. Abraxas recruits BRCA1 to DNA 331 
damage sites in response to IR. We thus examined the role of S404 phosphorylation in 332 
BRCA1 accumulation at the DNA damage sites. The percentage of cells containing 333 
more than 10 BRCA1 IR-induced foci (IRIF) as well as the intensity of the foci were 334 
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significantly decreased in Abraxas knockdown cells. While the defect of Abraxas 335 
knockdown cells in BRCA1 IRIF formation could be rescued by expression of wild-336 
type Abraxas, it could not be rescued by expression of Abraxas S406A or S404A 337 
mutant (Figure 5C, D and S5). Consistently, when we examined the chromatin-bound 338 
BRCA1 levels in response to IR, we found that the S404A mutant failed to 339 
accumulate BRCA1 to damaged chromatin in a similar way to the S406A mutant 340 
compared with the wild-type Abraxas does (Figure 5E). As a control, we 341 
demonstrated that the total expression level of BRCA1 was not affected in Abraxas 342 
knockdown cells or the cells complemented with expression of either wild type or 343 
mutants Abraxas. Thus, phosphorylation of S404 is likely to play an important role in 344 
BRCA1 accumulation to DNA damage sites and in cellular resistance to IR.  345 
 346 
Abraxas-dependent BRCA1 dimerization in vivo  347 
We tested whether BRCA1 forms dimers in vivo and whether the stable dimer 348 
formation is dependent on Abraxas. We co-expressed differentially Myc- or Flag-349 
tagged BRCA1 full-length protein in control (Ctrl) cells or Abraxas knockout (KO) 350 
cells. In the co-immunoprecipitation experiment with lysates prepared from cells 351 
treated with IR, immunoprecipitated Flag-BRCA1 interacts with Myc-tagged BRCA1 352 
indicating that BRCA1 indeed dimerizes in vivo. The dimerization was decreased in 353 
Abraxas knockout cells indicating the dependency of dimerization on Abraxas (Figure 354 
6A). Similarly, a construct containing only the BRCA1-BRCT domains also 355 
dimerizes when co-expressed in cells and the dimerization is decreased in Abraxas 356 
knockout cells (Figure 6B).  357 
We then tested whether the germline mutations F1662S and M1663K interfere 358 
with BRCA1 dimerization in vivo. We compared the interaction of a Myc-tagged full-359 
length BRCA1 and a HA-tagged wild-type BRCT fragment with that of the F1662S 360 
or M1663K mutant of BRCA1 and a mutant BRCA1 BRCT fragment with three 361 
residues localized in the dimer interface mutated (F1662S/M1663K/R1670E). Both 362 
the Myc- immunoprecipitation (Figure 6C) and reciprocal HA- immunoprecipitation 363 
(Figure 6D) experiments showed that the interaction/dimerization of BRCA1 and 364 
BRCT was decreased with mutation of the critical residues at the dimer interface 365 
F1662S or M1663K. Thus, BRCA1 germline mutations interfere with stable dimer 366 
formation in vivo. 367 
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To understand dimerization of the BRCT/Abraxas complex in vivo, we 368 
examined whether Abraxas forms a dimer in which the phosphorylated C-termini of 369 
Abraxas in complex with BRCT could be in close vicinity for dimerization. We 370 
expressed both GFP-tagged Abraxas and HA-Flag-tagged Abraxas in cells and tested 371 
whether the differentially tagged Abraxas molecules interact with each other using the 372 
immunoprecipitation assay. We found that wild-type Abraxas, as well as the S404A 373 
and S406A mutant, interacts with differentially tagged counterpart, indicating that 374 
Abraxas dimerizes/oligomerizes in vivo independently of its binding to BRCA1 375 
(Figure 6E). We then investigated what region of Abraxas mediates the dimerization 376 
by examining various deletion mutants of Abraxas. Deletion of the coiled-coil domain 377 
abolished the self-interaction of either wild-type or mutant Abraxas (Figure 6F and 378 
S6). Thus, in vivo, Abraxas dimerizes/oligomerizes through the coiled-coil domain. 379 
 380 
Discussion 381 
BRCA1 accumulation to DNA damage sites is a crucial step for BRCA1’s function in 382 
DNA damage repair and BRCT domains of BRCA1 are important for the tumor 383 
suppressor function of BRCA1. IR-induced ubiquitination at DNA damages sites 384 
generates docking sites for the recruitment of the Abraxas/BRCA1-A complex and 385 
accumulation of BRCA1 at sites of damage. Our data provide evidence for an IR-386 
induced, ATM-dependent mechanism specific to Abraxas-mediated recruitment of 387 
BRCA1. In such a model (Figure 7), IR-induced phosphorylation of S404 next to the 388 
pSPxF induces stable dimer formation of the BRCA1 BRCT/Abraxas complex. 389 
The crystal structural analysis of BRCT in complex with Abraxas 390 
phosphorylated peptides revealed that, although both single phosphorylated Abraxas 391 
peptide Ab1p and double phosphorylated Ab2p bind to BRCT domains through the 392 
same pSPxF motif, the phosphorylation of S404 in Ab2p induces stable dimerization 393 
of the BRCT/Abraxas complex. The dimer interface locates to the BRCT1 of BRCA1 394 
tandem BRCT domains. As expected from previous reports, BRCT1 also provides the 395 
interaction site for pS406 of the pSPxF motif while the side chain of F of the motif 396 
inserts into a hydrophobic pocket created mainly by BRCT2 domain. The dimer 397 
surface formed between two BRCT1 domains does not directly influence the 398 
interaction between the pSPxF motif and the BRCT domains. Although the 399 
hydrophobic D1 interface observed in the BRCT-Ab2p dimer was buried in a similar 400 
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manner in the BRCT-Ab1p or other BRCA1 BRCT related crystal structures to that 401 
previously described (Wu et al., 2015), this interaction is not strong enough to form a 402 
stable dimer in solution as we observed for BRCT domain only, BRCT-Ab1p, BRCT-403 
Bach1 or BRCT-CtIP. In contrast, under the same condition, the stable-dimer state of 404 
BRCT-Ab2p is triggered by the phosphorylation of S404. A phosphorylation-mimetic 405 
point mutant S404D stabilizes BRCT/Abraxas dimer formation in solution in a similar 406 
way to phosphorylated S404, further supporting the conclusion that phosphorylation 407 
of S404 promotes dimer formation. The impact of phosphorylation of Abraxas S404 408 
is the following: 1) the highly charged phosphate group of pS404 faces away from 409 
BRCT domains, resulting in stabilization of the interaction of the side chain of Y403 410 
with BRCT P1659 located at the N-terminus of D1. This interaction causes the shift of 411 
D1 closer to the N-terminus of the phosphopeptide; 2) the negatively charged side 412 
chains of pS404 and E402 provide extra ionic interaction sites with K1671 of BRCT. 413 
All together, this leads to a stable BRCT-Ab2p complex dimer formation. Owing to 414 
the symmetric pairing shape, we describe the BRCT-Ab2p dimerization interaction as 415 
a “pair-hugging” interaction mode, in which the Abraxas phosphopeptide acts as an 416 
arm wrapping around the other BRCT domain therefore stabilizing the interaction 417 
(Figure 7).  418 
The IR-induced phosphorylation of Abraxas S404 and the subsequent stable 419 
BRCA1-BRCT dimerization are likely to comprise an important mechanism for 420 
cellular response to IR since mutation of S404 leads to decreased BRCA1 421 
accumulation to DNA damaged chromatin and increased cellular sensitivity to IR. 422 
IR-induced phosphorylation of Abraxas S404 may facilitate the accumulation of 423 
BRCA1 at DNA damage sites by stabilizing the BRCA1 protein dimerization forming 424 
more stable higher order complexes at sites of damage. In addition, S404 425 
phosphorylation may further facilitate the interaction of Abraxas and BRCA1 by 426 
reducing the dissociation of pS406, so prolonging the Abraxas interaction with BRCT 427 
domains or limiting the accessibility of pS406 by other proteins such as phosphatase. 428 
Alternatively, induced dimerization of BRCA1 BRCT by phosphorylation of S404 of 429 
Abraxas could increase the local concentration of BRCA1 at damaged chromatin, 430 
which is likely critical for efficient DNA damage signaling and repair.  431 
Many tumor-derived truncation and missense mutations have been identified 432 
in the BRCA1 BRCT domains. While some of these mutations have been shown to 433 
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either destabilize the protein fold of the BRCT domains or disrupt the binding surface 434 
to pSPxF-containing phosphopeptides (Cantor et al., 2001; Clapperton et al., 2004; 435 
Coquelle et al., 2011; Manke et al., 2003; Shiozaki et al., 2004; Williams and Glover, 436 
2003; Williams et al., 2004; Yu et al., 2003), resulting in cancer predisposition, the 437 
function of a large number of BRCT mutations is still unknown (Easton et al., 2007). 438 
Our analyses reveal that germline mutations F1662S and M1663K disrupt the ability 439 
of BRCT to dimerize, in vitro and in vivo, providing a structural explanation for the 440 
possible role of these mutations in inactivating BRCA1 tumor suppressor function. 441 
Future study is needed to further characterize the effect of these mutations in the 442 
function of BRCA1 in DNA repair and damage signaling.  443 
            How is the dimerization of BRCT-Abraxas achieved in vivo? Since the 444 
phosphorylation of S406 is not IR-dependent, Abraxas binds to BRCA1 through the 445 
pSPxF motif even in the absence of DNA damage (Wang et al., 2007). The 446 
dimerization of Abraxas through the coiled-coil domain could potentially position the 447 
two BRCT tandem domains that interact at the C-terminus of Abraxas into close 448 
vicinity, leading to an unstable dimer of the BRCT-Abraxas complex in the absence 449 
of DNA damage.  In response to IR, IR-induced phosphorylation of S404 leads to an 450 
increase of affinity between the phosphate group and the residues at the dimer 451 
surface, which consequently results in a much more stable dimer complex of BRCA1 452 
BRCT/Abraxas. Since the coiled-coil domain of Abraxas also appears to dimerize 453 
with the coiled-coil domain of BRCC36 (Wang and Elledge, 2007), it is likely that, in 454 
the BRCA1-A complex, Abraxas and BRCC36 form an oligomeric bundle through 455 
the coiled-coil domain present on each of the Abraxas and BRCC36 molecule. Future 456 
structural analysis of the BRCA1-A complex is needed to further understand the 457 
multimerization of Abraxas and BRCC36 of the BRCA1-A complex. Nevertheless, 458 
IR-induced phosphorylation at Abraxas S404 appears to function as a regulatory 459 
switch, which leads to stable dimerization of two nearby BRCT domains.  460 
 The phosphorylation-induced BRCT dimerization is observed only in the 461 
BRCT/Abraxas complex. We demonstrate that, in addition to the pSPxF-binding 462 
motif, IR-induced phosphorylation of a nearby S404 residue can further regulate the 463 
interaction of BRCT and Abraxas. Thus, amino acid sequences outside the pSPxF 464 
motif may confer specificity in regulation of the BRCT binding to phosphorylated 465 
proteins. Indeed, in addition to phosphorylated S404, the N-terminal region of 466 
Abraxas peptide (GFGE402Y403pS404RpSPVF) also contributes to stable 467 
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BRCT/Abraxas dimer formation. The E402 residue cooperates with the 468 
phosphorylated S404 in stabilizing the dimer formation; the side chain of Y403 is 469 
fixed to interact with BRCT P1659 when S404 is phosphorylated. Thus the unique 470 
sequence feature outside of the pSPxF motif ensures that stable dimer formation 471 
occurs only with BRCT/Abraxas but not with other BRCT complexes. Since Abraxas-472 
BRCA1 interaction has been shown critical for DNA repair and maintenance of 473 
genomic stability, the additional regulatory mechanism uncovered in this study in 474 
regulating the interaction of Abraxas and BRCA1 further highlights the importance of 475 
this interaction in BRCA1 signaling and tumor suppression. 476 
In summary, our study reveals a phosphorylation-dependent mechanism in 477 
Abraxas-mediated recruitment and accumulation of BRCA1 at DNA damage sites, 478 
deepening our understanding of BRCA1 and Abraxas tumor suppressor function and 479 
related cellular signaling. Our study also provides structural insights that will assist 480 
the design of small molecules modulating BRCA1-Abraxas interaction in the future. 481 
 482 
Experimental Procedures 483 
Cell Lines, Culture and Antibodies 484 
U2OS cells were cultured in McCoy’s 5A medium supplemented with 10% FBS. 485 
293T cells were grown in Dulbecco’s modified Eagles medium (DMEM) 486 
supplemented with 10% FBS. Details of generation of Abraxas knockdown or 487 
knockout cells were described in the supplemental methods. Antibodies used are 488 
described in the supplemental methods. 489 
 490 
Immunofluorescence 491 
Cells were fixed with 3.6% formaldehyde for 10 min, permeabilized with 0.5% Triton 492 
X-100 solution and incubated with primary antibodies for 1 hr at 37oC followed by 493 
appropriate Alexa 488-conjugated (green; Invitrogen) and Alexa 555-conjugated (red; 494 
Invitrogen) secondary antibodies. Additional information is included in the 495 
supplemental methods. 496 
 497 
Cell Lysis and Immunoprecipitation 498 
Cell lysates were prepared from 293T cells or 293T Abra1-gene knockout cells either 499 
untreated or treated with 10 Gy IR followed by incubation at 37°C for 1 hr. Flag 500 
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immunoprecipitation (IP) was performed with lysates prepared from cells either 501 
treated or untreated with 10 Gy IR followed by 1 hr incubation at 37°C. Western blots 502 
were carried out using indicated antibodies. 293T cells were incubated with kinase 503 
inhibitors for 2 hr at indicated concentrations. Cells were then either exposed to 4 Gy 504 
IR or untreated. After 1 hr incubation, cells were lysed and Abraxas pS404pS406 505 
levels were determined by western blot. Additional information is included in the 506 
supplemental methods. 507 
 508 
Clonogenic Survival Assay 509 
Stable U2OS cell lines were seeded at low density in 10 cm dishes and irradiated with 510 
4 Gy ionizing irradiation using a 137Cs source. The cells were then cultured at 37°C 511 
for 14 days to allow colonies to form. Colonies were stained with 2% methylene blue 512 
and 50% ethanol for 10 min.  513 
Chromatin fractionation 514 
Abraxas knockdown cells complemented with vector, WT, S404A, S406A and double 515 
mutant (S404A, S406A) were irradiated at 10 Gy and incubated for 1 hr at 37°C. 516 
Cells were then subjected for chromatin fractionation followed by detection with 517 
indicated antibodies. Details are described in the supplemental methods. 518 
 519 
BRCT construct, purification, crystallization, and data collection 520 
Construction and purification of BRCA1 BRCT and mutants are described in the 521 
supplemental data. Purified BRCT was mixed with Abraxas peptides at a 1:3 molar 522 
ratio as has been previously reported (Shiozaki et al., 2004) and incubated at 4oC for 523 
30 minutes. Final protein concentration was 30 mg/ml. Crystallization was set up 524 
using the hanging-drop vapour diffusion method with drops containing 1 μl of protein 525 
sample and 1μl of crystallization solution. Crystals appeared after 3-4 days. BRCT-526 
Ab2p was crystallized in 0.1 M HEPES pH 7.0, 60 mM ammonium sulphate and 5% 527 
(w/v) PEG 4000. BRCT-Ab1p_short was crystallized in 1 M lithium chloride, 0.1 Tris 528 
pH 8.0 and 20% (w/v) PEG 6000. X-ray diffraction data were processed by XDS 529 
(Kabsch, 2010) and scala (Winn et al., 2011). The phases for the structure factors 530 
were obtained through molecular replacement using Phaser module in Phenix 1.8.4-531 
1496 (Adams et al., 2010). More detail of protein crystal and structure determination 532 
can be found in supplemental data. 533 
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 534 
Size exclusion chromatography for BRCT with Abraxas, Bach1 and CtIP 535 
phosphopeptides 536 
BRCT protein and Abraxas, Bach1 and CtIP peptides were mixed in a 1:3 molar ratio 537 
to a final concentration of 1mg/ml (about 40 μM) in 500 μl loops. Gel filtration was 538 
performed in Buffer A using Superdex75 10/300 column (GE Healthcare life) with a 539 
flow rate of 0.5 ml/min. For studying the high protein concentration effects on BRCT-540 
Abraxas complex formation, a final concentration of 10 mg/ml was used. Protein 541 
markers (GE Gel Filtration LMW Calibration Kit) were run following the kit protocol. 542 
 543 
Native mass spectrometry 544 
Samples were diluted to 15 or 75 μM protein concentration in 300 mM ammonium 545 
acetate pH 7.6 and further buffer exchanged into 300 mM ammonium acetate using 546 
Bio-Spin 6 (Bio-Rad) column. The desalted samples were loaded into the in-house 547 
prepared gold-coated glass capillaries (Hernández and Robinson, 2007). Nano-548 
electrospray mass spectrometric analyses were performed under native conditions on 549 
a hybrid quadrupole time-of-flight mass spectrometer previously modified for high 550 
mass transmission (Sobott et al., 2002). Typically the following instrumental 551 
conditions were used: capillary voltage 1.3 kV, sample cone 200 V and collision cell 552 
energy 5 V.  553 
 554 
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Figure Legends 726 
Figure 1: IR induced double phosphorylation of Abraxas C-terminus S404 and 727 
S406 is ATM-dependent. A) Abraxas-domain boundary and C-terminal sequence 728 
containing a serine residue (S404) next to the BRCA1-binding pSPxF motif (high-729 
lighted in blue). CC represents coiled-coil domain. Phosphorylation of S404 and S406 730 
is indicated as P. B) Double phosphorylation of S404 and S406 residues at the 731 
Abraxas C-terminus in response to IR in 293T cells and 293T/Abraxas knockout 732 
(KO) cells. Lysates from cells treated with 10 Gy IR followed by incubation at 37 °C 733 
for 1 h were used for western blot with anti-pS404pS406 antibody.   “*” non-specific 734 
band. C) IR-induced double phosphorylation of S404 and S406 is abolished in 735 
Abraxas mutants (S404A, S406A or double mutant (DM)).   “*” non-specific band.  736 
Flag- and HA-tagged Abraxas wild type (WT) or mutants were expressed in 293T 737 
cells. Lysates from cells treated with 10 Gy IR, incubated at 37 °C for 1 hr were used 738 
for immunoprecipitation with anti-Flag beads and western blot with antibodies against 739 
pS404pS406 and pS406 of HA. D) IR-induced double phosphorylation of S404 and 740 
S406 occurs immediately after IR treatment. Time-points were taken after cells were 741 
treated with 4 Gy IR followed by incubation at 37 °C. E) IR-induced phosphorylation 742 
occurs in a dose-dependent manner. F) ATM regulates IR-induced phosphorylation. 743 
Cells were incubated with ATM kinase inhibitor KU55933 (10 PM) for 2 hr before 744 
exposure to 4 Gy IR and subsequent incubation at 37°C for 1 hr. G) ATR is not 745 
involved in IR-induced double phosphorylation. ATR inhibitor VE-821 at indicated 746 
concentrations were used for treating cells for 2 hr before cells were exposed to 4 Gy 747 
IR. (See also Figure S1) 748 
Figure 2: Crystal structures of BRCT in complex with single and double 749 
phosphorylated Abraxas peptides. A) Crystal structure of BRCT-Ab1p_short. 750 
BRCT domains are in yellow, and Ab1p_short peptide is in wheat. B) C) and D) show 751 
the detailed interactions between phosphopeptide and BRCT domains. Polar 752 
interaction is indicated in dashed lines. E) Crystal structure of BRCT-Ab2p. BRCT is 753 
in blue and Ab2p peptide is in cyan. F) and G) show the interface between BRCT and 754 
Abraxas peptide in both BRCT-Ab1p_short and BRCT-Ab2p structures. 2Fo-Fc 755 
electron density (σ=1.0) is shown for Abraxas peptides. H) Superimposition of 756 
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BRCT-Ab2p, BRCT-Ab1p_short, BRCT-Bach1 (PDB code: 1T29) and BRCT-CtIP 757 
(PDB code: 1Y98). BRCT domains are shown in a grey surface representation. Ab2p 758 
is in blue, Ab1p_short is in yellow, Bach1 is in green and CtIP is in purple. The 759 
pSPxF Motif is indicated. I) Sequence alignment of Abraxas C-terminus. BRCT-760 
binding motif is indicated by a blue line. A black arrow indicates the half conserved 761 
residues. (See also Figure S2 and S3) 762 
Figure 3: Double phosphorylated Abraxas peptide induces dimerization of 763 
BRCT-Ab2p complex. A) Crystal structure of BRCT-Ab2p complex dimer viewed 764 
from three different directions. The two-fold axis is shown as a black arrow. The 765 
dimer interface is within the dashed circles and zoomed in B, C and D. B) Dimer 766 
interface between two BRCT α1 helices. C) Interaction between BRCT α1 helix and 767 
Ab2p. D) Dimer interface between two BRCT β2 strands. Polar interactions between 768 
labelled residues are shown in black dashed line. Key residues are indicated. E) 769 
Surface representation of BRCA1-1p_short (yellow) and BRCT-Ab2p dimer (blue 770 
and pink). Abraxas pS406 binding region is indicated in dashed circle. F) Gel 771 
filtration BRCT in complex with Ab1p, Ab2p, Bach1 and CtIP phosphopeptides at a 772 
concentration of 40 μM (1mg/ml). The regions for dimer complex (2:2 complex) and 773 
monomer complex (1:1 complex) are high lined in yellow and green shade. Elution 774 
positions for void and protein markers Aprotinin (Mw=6500Da), Ribonuclease A 775 
(Mw=13700Da), Carbonic anhydrase   (Mw=29000Da), Ovalbumin (44000 Da) and 776 
Conalbumin (Mw=75000Da) are indicated. G) The molecular weight of BRCT and its 777 
complexes with phosphopeptide, measured using native mass spectrometry. H) The 778 
native mass spectra of BRCT-Ab1p, BRCT-Ab2p, BRCT-Bach1 and BRCT-CtIP 779 
complexes tested at 15 μM. (See also Figure S3) 780 
 781 
Figure 4:  Mutagenesis studies of the interface of BRCT-Ab2p complex dimer. A) 782 
Simplified BRCT-Ab2p dimer interface containing three regions observed in BRCT-783 
Ab2p crystal.  B) Detailed interactions mediated though BRCT D1. C) Summary of 784 
BRCT and Abraxas mutants. Complexes tested are grouped into four and high-lined 785 
in different colours. D) Gel filtration of BRCT and Abraxas mutants. The same colour 786 
codes are used as in C. E) Surface representation of BRCA1-1p_short (yellow) and 787 
BRCT-Ab2p dimer (blue and pink). Abraxas pS406 binding region is indicated in 788 




Figure 5: Phosphorylation of S404 and S406 are both important for cellular 792 
resistance to IR and BRCA1 accumulation at DNA damage sites. A) Generation 793 
of Abraxas knockdown U2OS cells complemented with expression of shRNA-794 
resistant HA-tagged wild type, S404A or S406A mutants of Abraxas. B) Increased 795 
cellular sensitivity to IR of Abraxas-deficient cells expressing mutants of Abraxas. 796 
Colony-survival assay was carried out for cells treated with 4 Gy IR. Data are 797 
presented as means ± s.d. Data analyses are processed by ANOVA and statistical 798 
significance was determined by Tukey’s multiple comparisons test. * P<0.02.  Three 799 
independent experiments were performed. Additional data are presented in Figure S5. 800 
C) Representative images of BRCA1 IRIF in Abra1 shRNA knockdown cells 801 
complemented with vector, wild-type or mutants of Abraxas in response to 10 Gy IR 802 
followed by 2 hr incubation at 37°C. D) The percentage of cells containing more than 803 
10 BRCA1 IRIF foci was quantified. Data are presented as means ± s.d.  Data 804 
analyses are processed by ANOVA and statistical significance was determined by 805 
Tukey’s multiple comparisons test. * P<0.0001.  At least three independent 806 
experiments were performed. More than 300 cells were counted for each experiment. 807 
Additional data for quantification at different time points post IR are presented in 808 
Figure S5. E) Quantification of the intensity of BRCA1 IR induced foci (IRIF). Data 809 
are presented as means ± s.d. (n>50).  Statistical analysis was carried out by Student’s 810 
t-test. * P<0.0002. F) BRCA1 accumulation at damaged chromatin depends on both 811 
S404 and S406 residues. Orc2 was used as a marker for chromatin-bound fraction. 812 
Cells were treated with 10 Gy IR followed by 2 h incubation at 37°C. Cellular 813 
fractionation was carried out and the chromatin fraction was analyzed. (See also 814 
Figure S5) 815 
 816 
Figure 6. Abraxas promotes BRCA1 BRCT dimerization in vivo. A) Abraxas-817 
dependent BRCA1 dimerization in vivo. Differentially Myc- and Flag-tagged BRCA1 818 
full-length constructs were transiently transfected into parental 293T (Ctrl) or 819 
Abraxas knockout (KO) cells. Lysates from cells treated with 10 Gy IR followed by 1 820 
hr incubation at 37°C were used for Flag-immunoprecipitation. Intensity of individual 821 
bands was quantified by densitometric analysis using NIH ImageJ software. 822 
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Normalized value (IPed_mycBRCA1/Input_mycBRCA1) was shown in the bar 823 
graph. B) Abraxas-dependent BRCA1-BRCT domains dimerization in vivo. 824 
Differentially Myc- and HA-tagged BRCA1-BRCT domains constructs were 825 
transiently transfected into parental 293T (Ctrl) or Abraxas knockout (KO) cells. 826 
Lysates from cells treated with 10 Gy IR followed by 1 hr incubation at 37°C were 827 
used for HA-immunoprecipitation. Band intensity was quantified with NIH imageJ 828 
software. Normalized value (IPed_mycBRCT/Input_mycBRCT) was shown in the bar 829 
graph. C) and D) BRCA1 germline mutations F1662S or M1663K decrease BRCA1 830 
dimerization in vivo. Myc-tagged BRCA1 full-length (WT-FL) and HA-tagged 831 
BRCA1 BRCT (WT-BRCT) or Myc-tagged mutant full-length (F1662S or M1663K) 832 
and HA-tagged BRCT triple mutant (TM, F1662S/M1663K/R1670E) were co-833 
expressed in cells. Lysates from cells treated with 10 Gy IR followed by 1 h 834 
incubation at 37°C were prepared for either Myc- immunoprecipitation (C) or 835 
reciprocal IP with HA- immunoprecipitation (D). Normalized value was shown in the 836 
bar graph. E) Abraxas dimerize/oligomerize in vivo independent of binding to 837 
BRCA1. Differentially tagged GFP- and HA-Flag-tagged wild type (WT) or GFP-838 
tagged and HA-Flag-tagged Abra1 mutants (S404A or S406A) were co-expressed in 839 
cells. Anti-GFP immunoprecipitation was carried out with lysates from 293T cells 840 
treated or not treated with 10 Gy IR followed by 1 hr incubation at 37°C. The images 841 
are from the same blot. F) Abraxas dimerizes/oligomerizes, in vivo, through the 842 
coiled-coil domain. Immunoprecipitations were carried out with lysates prepared from 843 
cells co-expressing HA-Flag-tagged wild-type Abra1 or HA-Flag-tagged coiled-coil 844 
domain deletion mutant (∆CC) and GFP-tagged wild type or ∆CC. (See also Figure 845 
S6) 846 
 847 
Figure 7. A Model showing IR-induced phosphorylation of Abraxas promotes 848 
dimerization of BRCA1 at sites of DNA damage for BRCA1 accumulation and 849 
cellular response to IR. In the absence of IR, two BRCA1 bound to BRCA1-A 850 
complex do not form stable dimer. Extra phosphorylation at Abraxas S404 induced by 851 
IR leads to the final stable dimerization of BRCA1 in the DNA damaged site. The 852 
BRCT-Abraxas interaction is indicated in dashed circle for “Pair hugging” interaction 853 
model. BRCT domains are represented by grey circles and Abraxas phosphopeptides 854 
by pink lines. Line with double arrows indicates interaction for dimerization. P 855 
indicates the phosphorylation. 856 
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Table 1: The statistics of structures  858 
Crystals BRCT-Ab1p_short BRCT-Ab2p 
X-ray source Diamond Light Source Beamline 
I03 
Diamond Light Source Beamline 
I04-1 
Wavelength (Å) 0.9793 0.9200 




63.8, 63.8, 93.4, 90, 90, 120 86.8, 183.7, 190.5, 90, 90, 90 
Resolution (Å) 47.6-2.5 95.3-3.5 
bRsym 0.051 (0.498) a 0.096 (0.701) 
I / σ 24 (5.1) 16.4 (2.6) 
Wilson B factor 58.6 97.2 
Completeness (%) 99.9 (99.8) 99.8 (98.8) 
Redundancy 9.3 (9.4) 7.4 (7.8) 
Refinement 
Resolution  (Å) 47.6-2.5 (2.6-2.5) 95.3-3.5 (3.7-3.5) 
No. Unique Reflections 8000 39170 
cRcryst 0.215 (0.356) 0.235 (0.319) 
dRfree 0.252 (0.374) 0.298 (0.341) 
No. Protein atoms 1,701 14,092 
No. Copy number of 





Average B-factor (Å2) 66.68 114.6 
R.m.s. deviations 
Bond lengths (Å) 0.007 0.007 
Bond angles (˚) 0.823 0.900 
 859 
aThe statistics in parenthesis are for the highest resolution shell 860 
bRsym=Σh|Ih -<I>|/ΣhIh, where Ih is the intensity of reflection h, and <I> is the mean 861 
intensity of all symmetry-related reflections. 862 
cRcryst=Σ||Fobs|-|Fcalc||/Σ|Fobs|, Fobs and Fcalc are observed and calculated structure factor 863 
amplitudes. 864 
dRfree as for Rcryst using a random subset of the data (about 10% for BRCT-Ab1p_short 865 
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Figure S1 (related to Figure 1): IR-induced double phosphorylation of Abraxas C-terminus S404 
and S406 is ATM-dependent, not ATR-, DNAPK-, Chk1- or Chk2 -dependent. Cells were 
incubated with Chk1 inhibitor (UCN-01), Chk1/2 inhibitor (AZD7762, 10 uM), ATM inhibitor 
(KU55933, 10 uM), DNA-PK inhibitor (NU7741, 10uM) for 2 hr at indicated concentrations. Cells 
were then either exposed to 4 Gy IR or untreated followed by 1 hr incubation at 37°C. Abraxas 
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Figure S2 (related to Figures 2 and 3): Electron density for Abraxas phosphopeptide and 
arrangement of BRCT-Ab2p molecules in the crystal asymmetric unit. A) Fo-Fc map (σ=3.0) is 
shown for Ab1p_short and Ab2p. B) 8 copies of BRCT-Ab2p in one asymmetric unit of the cell (space 
group P212121) were coloured in yellow, magenta, cyan, tint, green, orange, blue and grey individually. 
The same dimer interface occurs in each dimer of the BRCT-Ab2p complex. BRCT-Ab2p molecules 
belong to different ASUs are coloured in black. Each BRCT-Ab2p complex dimer unit was circulated 
in dashed line. The dimer interface is highlighted in grey and indicated by a black arrow. !
!
 
Figure S3 (related to Figure 3): Comparison of BRCT-Abraxas structures with other related 
BRCA1-BRCT structures, further experiments on the BRCA1-Abraxas complex in solution and 
native mass spectrometry. A) Superimposition of both BRCT-Ab1p_short (BRCT in yellow and 
Ab1p_short in wheat colour) and BRCT–Ab2p (BRCT in blue and Ab2p in cyan) structures by 
aligning the pSPTF motif and the BRCT binding pocket (α2, α1′ and α3′). N- and C-termini are 
indicated. The black dashed circle highlights the relative structural movements in 1 and 3 and is 
further zoomed in and rotated 90 degrees. B) Superimposition of BRCT-Ab2p with other BRCT related 
structures: BRCT-Ab2p (blue), BRCT-Ab1p_short (yellow), BRCT-Bach1 (PDB: 1T15 (cyan) and 
1T29 (red) (Clapperton et al., 2004; Shiozaki et al., 2004), BRCT with tetrapeptide motifs (PDB: 3K0K 
(orange) and 3K0H (wheat)) (Campbell et al., 2010), BRCT with acetyl-coA carboxylase 1 peptide 
(PDB:3COJ (pink)) (Shen and Tong, 2008) , BRCT-CtIP (PDB: 1Y98 (black)) (Varma et al., 2005), 
ATRIP (PDB: 4IGK (dark green)) (Liu and Ladias, 2013), optimized peptide (PDB:1T2V (light green)) 
(Williams et al., 2004) and BAAT1 (PDB:4IFI (white)) (Liu and Ladias, 2013). C) Superimposition of 
BRCT-Ab2p with BRCT-Optimized peptide (PDB code: 1T2V). The positions of related residues are 
relative to the phosphorylated serine in pSxxF is in the 0 position. D) Elution profile of BRCT only, 
BRCT-Ab_no_phosphorylation and BRCT-Ab pS404 are superimposed. BRCT, BRCT-Ab_pS404 and 
BRCT-Ab_no_phosphorylation are eluted at similar positions. E) BRCT-Ab1p and BRCT-Ab2p at 
high concentration (10 mg/ml). (F) Native mass spectra of BRCT-Abraxas complexes. Protein samples 
are tested at 75 µM concentration.  
!
Figure S4 (related to Figure 4). Identification of BRCT-Abraxas using SAXS. A) The SAXS 
scattering profiles of BRCT-Ab2p at 2 mg/ml (green), 5 mg/ml (blue) and 10 mg/ml (pink) are shifted 
up compared to those of BRCT-Ab1p for clarity. The black line is simulated-scattering profiles of the 
crystal structure of BRCT-Ab2p 2:2 dimer complex. B) Guinier plots of BRCT-Ab1p and BRCT-
Ab2p. The scattering data (dot; s<1.3/Rg) are shown together with linear fit lines (black). C) Rg and 
Dmax values of BRCT-Ab1p and BRCT-Ab2p. D) Pairwise distance-distribution functions of BRCT 
domains. The distribution functions of BRCT-Ab1p at 2 mg/ml (green) and 10 mg/ml (purple) are 
shown together with that of BRCT-Ab2p 2 mg/ml (red) and BRCT-Ab2p 10 mg/ml (blue). Each 
distribution function was normalized so that its total area value is 1. E) Concentration dependence of 
I(0) and radius of gyration Rg of BRCT-Ab1p (pink) and BRCT-Ab2p (blue). The top panel shows the 
plots of the concentration c versus c/I(0). The lower panel shows the plots of c versus the square of Rg. 
The top and lower panels share the same abscissa axis.  BRCT-Ab1p and BRCT-Ab2p are represented 
by pink and blue respectively. F) Shape reconstruction of BRCT-Ab2p. The structure of BRCT-Ab2p 






Figure S5 (related to Figure 5): Phosphorylation of S404 and S406 are both important for 
cellular resistance to IR and BRCA1 accumulation at DNA damage sites. A) An independent 
colony survival assay for Abraxas-deficient cells expressing WT or mutants of Abraxas treated with 4 
Gy IR. Data are presented as means ± s.d. Data analyses are processed by ANOVA and statistical 
significance was determined by Tukey’s multiple comparisons test. B) Representative images of 
BRCA1 IRIF in Abra1 shRNA knockdown cells complemented with vector, wild-type or mutants of 
Abraxas in response to 10 Gy IR followed by 2 hr incubation at 37°C. C) Quantification of the 
percentage of cells containing more than 10 BRCA1 IRIF foci at indicated time points after 10 Gy IR 






Figure S6 (related to Figure 6): Abraxas forms dimers through the coiled-coil domain 
independent of binding to BRCA1. A) A schematic view of the Abraxas deletion mutants generated. 
B) The coiled-coil domain is required for Abraxas dimerization. HA-Flag-tagged wild type (WT) 
Abraxas were co-transfected with GFP-tagged WT or deletion mutants of Abraxas into 293T cells. 48 h 
after transfection, cell lysates were prepared and used for Flag-immunoprecipitation. Western blots 
with GFP or HA antibodies are shown. Expression of GFP-tagged WT or mutant-Abraxas protein 
products are indicated with “*”. C) Abraxas coiled-coil deletion mutant (ΔCC) retains interaction with 
other components of the BRCA1-A complex. HA-Flag-tagged WT or ΔCC were transiently expressed 
in 293T cells. The samples in the upper panel were prepared from cells not treated with ionizing 
radiation. The lower panel shows the interaction of Abraxas with BRCC36.  An Abraxas mutant 
(R361W) that retains the interaction with BRCC36 was also used as a control. Samples of cells treated 
with 10 Gy IR or untreated were used to show the interaction of Abraxas with BRCC36. Flag-
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Supplemental Experimental Procedures 
Cell Lines, Cell Culture and Antibodies 
To generate Abraxas knockdown cells, U2OS cells were infected with retrovirus containing shRNAs 
against Abraxas followed by selection with puromycin (0.8 ug/ml) for 5 days. The Abraxas knockdown 
stable cell line was then complemented with expression of empty MSCV vector or expression 
constructs containing HA-tagged WT or mutant Abraxas, and selected with Blasticidin (9 ug/ml) 1 
week for stable expression. 293T Abraxas knockout cells were generated by CRISPR-Cas9 system (Fu 
et al., 2014; Ran et al., 2013) In brief, 293T cells were infected with lentivirus carrying pLentiCRISPR 
including Cas9 and sgRNA, which targets Abraxas genomic sequence 5’-
GGCGGCGGTAGCATGGA-3’. Cells were then subjected to puromycin selection (2 ug/ml) for three 
days and plated in low density for culturing for ten days. Single colonies were selected and knockout 
cells were confirmed by Western blotting with Abraxas antibody and PCR-sequence of the Abraxas 
genomic locus. Rabbit anti-Abraxas double-phosphorylated pS404pS406 antibody was generated using 
conjugated GFGEYpSRpSPTF phosphopeptide. The rabbit anti-Abraxas and anti-Abraxas S406 
antibodies were generated as previously described (Wang et al., 2007). Other antibodies used were 
BRCA1 antibodies (D9, Santa Cruz Biotechnologies); GFP antibodies (Invitrogen); γ-tubulin 




Abra1 shRNA knockdown cells complemented with empty vector, wild type or mutants of Abra1 were 
analyzed for BRCA1 IR-induced foci formation (IRIF). At least 500 cells were counted for each cell 
type and cells containing more than 10 foci were counted as positive. Mean and standard deviations are 
shown in the Figures 5B,D,E, S5A and statistical analysis was performed by student’s t-test or 
ANOVA with Tukey’s multiple comparisons test. p-value is as indicated. All images were obtained 
with a Nikon TE2000 inverted microscope with a Photometrics Cool- Snap HQ camera. Quantification 
of BRCA1 was performed using Imaris software (Bitplane). The DAPI channel was used to select the 
nuclei of the cells in the field, red and green channel were used for BRCA1 and γH2AX, respectively. 
For BRCA1 foci intensity measurement, foci were defined as particles bigger than 0.25 µM in diameter 
with an intensity cut-off value (1200) to eliminate background. At least 50 cells were counted and 
plotted using GraphPad Prism software. 
 
Cell Lysis and Immunoprecipitation 
Cells were lysed in NETN buffer (50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 1 mM EDTA, 0.5% 
Nonidet P-40) with protease inhibitors and protein phosphatase inhibitors, 1 mM NaF, and 1 mM 
Na3VO4. For Flag IP, cell lysates were incubated with Flag beads (Sigma) overnight with gentle 
agitation at 4oC. The beads were washed with NETN lysis buffer four times and eluted with 3X sample 
buffer for Western blot analysis. For analyzing Abraxas dimerization in vivo, GFP-tagged and HF-
tagged Abraxas wildtype, S404A, S406A mutant or coiled-coil deletion mutant were transiently 
transfected to 293T cells. Two days after transfection, cells were either untreated or exposed to 10 Gy 
IR. 2 hr later, cells were collected for GFP- or Flag- IP and Western blot was probed with either 
antibodies against HA or GFP. For analyzing BRCA1 dimerization in vivo, Flag- or Myc-tagged 
BRCA1 full-length wild type or mutants, or HA- and Myc-tagged BRCA1 BRCT fragments were 
analyzed in a similar way. ATM inhibitor (KU55933), ATR inhibitor (VE-821), DNA-PK inhibitor 
(NU7441) and Chk1/2 inhibitor (AZD7762) were purchased from Selleckchem and dissolved in 
dimethyl sulphoxide (DMSO). 
 
Clonogenic Survival Assay 
Abra1 shRNA knockdown cells complemented with empty vector, wild type or mutants of Abra1 were 
analyzed for cell survival in response to IR. Stable U2OS cell lines were seeded at low density in 10 
cm dishes and irradiated with 4 Gy ionizing irradiation using a 137Cs source. The cells were then 
cultured at 37°C for 14 days to allow colonies to form. Colonies were stained with 2% methylene blue 
and 50% ethanol for 10 min. Colonies containing 50 or more cells were counted as positive and 
statistical data were analyzed by analysis of variance (ANOVA) with Tukey’s multiple comparisons 
test.  
Chromatin fractionation 
Cells were irradiated at 10 Gy followed by 1 hr incubation at 37oC. For total cell extracts, cells were 
lysed in NETN150 buffer containing protease inhibitor mixture and analyzed by Western blot. For 
chromatin fractionation, irradiated cells were washed in PBS and resuspended in Buffer A (10 mM 
Hepes pH 7.9, 10 mM KCl, 1.5 mM MgCl2, 0.34 M sucrose, 10% glycerol, 5 mM NaF, 1 mM  Na3VO4 
, 1 mM  dithiothreitol (DTT), and protease inhibitor mixture) containing 0.1% Triton X-100, and 
incubated on ice for 5 min for permeabilization. The cytosolic fraction was then separated by 
centrifugation at 4000 rpm for 5 min at 4°C. The supernatant was discarded and the nuclei pellet was 
washed once with Buffer A and resuspended in Buffer B (3 mM EDTA, 0.2 mM EGTA, 1 mM DTT, 
protease inhibitor mixture) and incubated for 30 min on ice. The soluble nuclear fraction was separated 
by centrifugation at 4500 rpm for 5 min. The chromatin fraction pellet was washed with Buffer B and 
resuspended in 100 µl Laemmli sample buffer and sonicated for 10 sec before analysis. 
 
BRCT constructs, expression and purification 
The BRCT domains (residues 1646-1859) of the BRCA1 gene were amplified from IMAGE cDNA (ID 
7961446) using PCR and cloned into the pHAT2 vector (with noncleavable N-terminal His-tag) 
(Peränen et al., 1996) and transformed into RosettaTM2 (DE3) cells (Invitrogen). Cell culture was 
grown in LB medium till the OD600 was approximately 0.6. IPTG was added to a final concentration of 
1 mM and cells were grown overnight at 16oC. 1 g of harvested cells was resuspended with 10 ml of 
lysis buffer (50 mM Tris pH 8.0, 300 mM NaCl, 20 mM imidazole and one protease inhibitor tablet per 
50 ml lysis buffer). Cells were lysed using sonication. The supernatant after centrifugation was then 
filtered by 0.45 µm filter and loaded onto HisTrap HP 5ml (GE healthcare) pre-equilibrated with 
binding buffer (50 mM Tris pH 8.0, 300 mM NaCl and 20 mM imidazole) After washing with 10x 
column volume of binding buffer and binding buffer with 50 mM imidazole, the protein was eluted 
using elution buffer (50 mM Tris pH 8.0, 300 mM NaCl and 200 mM imidazole).  The eluted BRCT 
domains were about 80% pure as assessed by 12% SDS-PAGE. Remaining contaminants were 
removed by gel filtration using a Superdex 75 10/300 equilibrated with Buffer A (20 mM Tris pH 8.0, 
150 mM NaCl and 5 mM DTT). Fractions containing pure BRCT sample were analyzed in 12% SDS-
PAGE gel, pooled, concentrated and stored at -80oC. All mutants were made by site-directed 
mutagenesis using wt BRCT in pHAT2 as PCR template. Mutant proteins were expressed and purified 
using the procedure described above. 
 
Phosphopeptides 
All phosphopeptides were synthesized to above 95% purity without modification at both N and C 
terminus (Biomatik). Peptides were dissolved in Buffer A to 25 mg/ml. The pH of the peptide solution 
was adjusted to near pH 8 using 0.5 M NaOH. The peptide names and sequences are listed below: 
Abraxas peptides: 1)Ab1p: GFGEYSRpSPTF; 2)Ab2p: GFGEYpSRpSPTF; 3)Ab1p_short: 
YSRpSPTF; 4)Ab2p_short: YpSRpSPTF; 5)Ab_pS404: GFGEYpSRSPTF; 6)Ab_no_phosphorylation: 
GFGEYSRSPTF; 7)Ab2p(Y403A): GFGEApSRpSPTF; 8)Ab2p(Y403A)_short: ApSRpSPTF; 
9)Ab2p(F400D): GDGEYpSRpSPTF; 10)Ab2p(E402R): GFGRYpSRpSPTF; 11)Ab1p(S404P): 
GFGEYPRpSPTF; 12)Ab1p(S404D): GFGEYDRpSPTF; 13)Bach1: ISRSTpSPTFNKQ; 14) CtIP: 
PTRVSpSPVFGAT 
 
Protein crystallization and data collection 
Crystals were cryoprotected in crystallization solution containing 30% glycerol using the two-step 
transferring method and then subsequently flash frozen in liquid nitrogen. The structure of BRCT-
Bach1 (PDB code 1T15) (Clapperton et al., 2004) without Bach1 phosphopeptide was used as the 
search model. Relaxed NCS restraints among all the molecules of the BRCT-Ab2p in the asymmetric 
unit were used in the refinement protocol as defined in phaser_refine module. This resulted in clear 
2Fo-Fc and Fo-Fc electron density that allowed manual building of the Abraxas peptide using Coot 
(Emsley et al., 2010) (Figure S1). For BRCT-Ab2p, the structure connectivity and disordered region 
vary among molecules in the ASU depending on its position in the crystallographic packing, therefore 
chains IDs G, H, O and P have poorer electron density map than other chains.  Further structure 
refinements also included simulated annealing, optimizing X-ray/Stereochemistry weight, optimizing 
X-ray/ADP weight and side chain adjustment using Coot. The buried surface area after dimerization of 
BRCT-Ab2p was calculated using PISA (Krissinel and Henrick, 2007). 
 
Identification of BRCT-Ab1p and BRCT-Ab2p using SAXS 
We carried out SAXS of the BRCT-Ab1p and BRCT-Ab2p in different concentrations. The scattering 
profiles (Figure S4A) of BRCT-Ab1p and BRCT-Ab2p at high concentration (10 mg/ml) were similar 
and indicated that the samples were monodisperse (Figure S4B). The scattering profiles of BRCT-
Ab2p did not change by increasing the concentration of the sample whereas BRCT-Ab1p changed 
particularly at low angle. We then used the BRCT-Ab2p dimer crystal structure to calculate its 
scattering profile and compare it with the observed profile of BRCT-Ab2p (black line in Figure S4A). 
The calculated-scattering profiles of the 2:2 BRCT-Ab2p dimer explain the observed scattering profiles 
much better than for the 1:1 complex  (χ=1.675 and 3.806 respectively) indicating that BRCT-Ab2p is 
dimerized in solution. The fitting of the 2:2 dimer structure against the scattering profile of BRCT-
Ab1p was better at 10 mg/ml (χ=1.934) than at 2 mg/ml (χ=5.975). The pairwise distance-distribution 
functions of BRCT-Abraxas complexes showed that BRCT-Ab2p has a very similar profile at both 10 
mg/ml and 2 mg/ml concentrations. They both have a shoulder around 50 Å (indicated by black arrow 
in Figure S4D), which is clearer than that of BRCT-Ab1p at 10 mg/ml and 2 mg/ml. Furthermore, 
BRCT-Ab1p showed inter-particle attraction by increasing the concentration of the sample but BRCT-
Ab2p did not (Figure S4E) (Nakasako et al., 2005). BRCT-Ab2p complex dimer crystal structure can 
be fitted into the envelope of an averaged DAMMIN model of the dimer (Figure S4F). 
 
SAXS analysis 
SAXS data of 2, 5 and 10 mg/ml BRCT-Ab1p and BRCT-Ab2p in Buffer A (20 mM Tris pH 8.0, 150 
mM NaCl and 5 mM DTT) were collected at I22 in Diamond Light Source. Protein samples were 
loaded into glass capillaries using a BIOSAXS robot and the scattering intensities of the sample were 
measured at 5oC using the Pilatus 2M detector. The scattering vector s is 4πsinθ/λ, where θ is half of 
the scattering angle and λ is the wavelength (0.9987 Å). Data reduction was carried out using DAWN. 
Primus was used to interpolate to the zero concentration of BRCT-Abraxas2p data using the ZeroConc 
module and to calculate Rg & I(0) using the AutoRg module and pair-distribution functions & Dmax 
using the AutoGNOM module (Figure S4C) (Petoukhov et al., 2012). Ten dummy-residue models of 
BRCT-Ab2p were created using DAMMIN (Svergun, 1999) and were superimposed and averaged 
using SUPCOMB (Kozin and Svergun, 2001) and DAMAVER (Volkov and Svergun, 2003) to 
generate a dummy-residue model of BRCT-Ab2p. The mean value of normalized-spatial discrepancy 
was 0.567. The selection of the best-fit model was conducted as follows. The missing N-termini of the 
BRCT domains and the peptide from BRCT-Ab2p crystal structure were added by Coot (Emsley et al., 
2010). RapperTK (Gore et al., 2007) was used to generated 100 conformations of these flexible 
structures. A conformation of each chain was randomly selected and mixed to generate 1000 
conformations of BRCT-Ab2p. The fitting of each conformation was calculated using CRYSOL to 
select the best conformation. 
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